Payment overview · 2025
General Payments
$89,405.95
65 reported records · 14 companies
Healthcare provider profile · identity verified
Firas El Chaer, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology · MIAMI, FL · NPI 1659624856
Verified facts
What the public records show
CMS Open Payments records show Firas El Chaer, M.D. received $89,405.95 in general payments during 2025 across 65 reported records.
Syndax Pharmaceuticals, Inc. accounted for 38.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Besremi, Ojjaara, Venclexta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VENCLEXTA as an associated drug or biological on 10417 records involving 4944 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Venclexta by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OJJAARA as an associated drug or biological on 12602 records involving 5639 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Ojjaara by this doctor in 2024.
PharmaEssentia USA Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BESREMI as an associated drug or biological on 6276 records involving 3476 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Besremi by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Syndax Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $34,607.79 | 38.7% | 26 | 2025 |
| PharmaEssentia USA Corporation | Unresolved — no canonical attribution shown | $24,372.42 | 27.3% | 9 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $11,859.53 | 13.3% | 9 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $4,750.00 | 5.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $3,806.19 | 4.3% | 7 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $2,829.57 | 3.2% | 2 | 2025 |
| TAIHO ONCOLOGY, INC. | Unresolved — no canonical attribution shown | $2,340.00 | 2.6% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $2,240.00 | 2.5% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $1,578.53 | 1.8% | 3 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $650.00 | 0.7% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $141.36 | 0.2% | 2 | 2025 |
| SOBI, INC | Unresolved — no canonical attribution shown | $120.06 | 0.1% | 1 | 2025 |
| SANOFI US SERVICES INC. | Unresolved — no canonical attribution shown | $83.20 | 0.1% | 1 | 2025 |
| Geron Corporation | Unresolved — no canonical attribution shown | $27.30 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $43,448.50 | 15 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $26,400.00 | 8 |
| Education | $8,954.75 | 1 |
| Travel and Lodging | $8,662.70 | 19 |
| Food and Beverage | $1,940.00 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REVUFORJ Normalized: revuforj |
Drug | Syndax Pharmaceuticals, Inc. | $34,583.94 | 25 | 2025 |
Source payment records
|
|||||
| BESREMI Normalized: besremi |
Drug | PharmaEssentia USA Corporation | $24,372.42 | 9 | 2025 |
Source payment records
|
|||||
| OJJAARA Normalized: ojjaara |
Drug | GlaxoSmithKline, LLC. | $4,750.00 | 1 | 2025 |
Source payment records
|
|||||
| BLINCYTO Normalized: blincyto |
Biological | Amgen Inc. | $3,806.19 | 7 | 2025 |
Source payment records
|
|||||
| INQOVI Normalized: inqovi |
Drug | TAIHO ONCOLOGY, INC. | $2,340.00 | 1 | 2025 |
Source payment records
|
|||||
| VENCLEXTA Normalized: venclexta |
Drug | ABBVIE INC. | $1,578.53 | 3 | 2025 |
Source payment records
|
|||||
| Vanflyta Normalized: vanflyta |
Drug | Daiichi Sankyo Inc. | $650.00 | 1 | 2025 |
Source payment records
|
|||||
| SARCLISA Normalized: sarclisa |
Biological | GENZYME CORPORATION | $141.36 | 2 | 2025 |
Source payment records
|
|||||
| Vonjo Normalized: vonjo |
Drug | SOBI, INC | $120.06 | 1 | 2025 |
Source payment records
|
|||||
| AYVAKIT Normalized: ayvakit |
Biological | SANOFI US SERVICES INC. | $83.20 | 1 | 2025 |
Source payment records
|
|||||
| Fabhalta Normalized: fabhalta |
Drug | Novartis Pharmaceuticals Corporation | $29.57 | 1 | 2025 |
Source payment records
|
|||||
| SCEMBLIX Normalized: scemblix |
Drug | Novartis Pharmaceuticals Corporation | $29.57 | 1 | 2025 |
Source payment records
|
|||||
| RYTELO Normalized: rytelo |
Drug | Geron Corporation | $27.30 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BESREMI besremi |
2025 | Besremi | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| OJJAARA ojjaara |
2025 | Ojjaara | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VENCLEXTA venclexta |
2025 | Venclexta | 2024 | 53 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VENCLEXTA open payments reported associated product |
CMS Open Payments — General Payments 10417 supporting records · 4944 recipient NPIs · example record 1201353144 |
Venclexta · 2024 Exact normalized brand match · 1 Part D row |
53 | 14 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | OJJAARA open payments reported associated product |
CMS Open Payments — General Payments 12602 supporting records · 5639 recipient NPIs · example record 1190332357 |
Ojjaara · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| PharmaEssentia USA Corporation Exact reporting entity; no affiliate inference |
2025 | BESREMI open payments reported associated product |
CMS Open Payments — General Payments 6276 supporting records · 3476 recipient NPIs · example record 1246822425 |
Besremi · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Acyclovir | Acyclovir | 53 | 12 |
| Venclexta | Venetoclax | 53 | 14 |
| Ojjaara | Momelotinib Dihydrochloride | 31 | suppressed |
| Besremi | Ropeginterferon Alfa-2b-Njft | 30 | suppressed |
| Sprycel | Dasatinib | 22 | suppressed |
| Imatinib Mesylate | Imatinib Mesylate | 20 | suppressed |
| Jakafi | Ruxolitinib Phosphate | 20 | suppressed |
| Posaconazole | Posaconazole | 18 | suppressed |
| Lenalidomide | Lenalidomide | 17 | suppressed |
| Allopurinol | Allopurinol | 16 | suppressed |
| Famotidine | Famotidine | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Inrebic | Fedratinib Dihydrochloride | 13 | suppressed |
| Bosulif | Bosutinib | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $89,405.95 · 65 records | Syndax Pharmaceuticals, Inc. | AYVAKIT, BESREMI, BLINCYTO, Fabhalta, INQOVI, OJJAARA, REVUFORJ, RYTELO, SARCLISA, SCEMBLIX, VENCLEXTA, Vanflyta, Vonjo | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Besremi play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error